SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-053602
Filing Date
2020-11-12
Accepted
2020-11-12 16:27:30
Documents
55
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tsha-10q_20200930.htm 10-Q 1944223
2 EX-10.7 tsha-ex107_186.htm EX-10.7 66391
3 EX-31.1 tsha-ex311_11.htm EX-31.1 18325
4 EX-31.2 tsha-ex312_10.htm EX-31.2 18349
5 EX-32.1 tsha-ex321_9.htm EX-32.1 9818
6 EX-32.2 tsha-ex322_8.htm EX-32.2 9833
  Complete submission text file 0001564590-20-053602.txt   5445692

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT tsha-20200930.xml EX-101.INS 690771
8 XBRL TAXONOMY EXTENSION SCHEMA tsha-20200930.xsd EX-101.SCH 48309
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tsha-20200930_cal.xml EX-101.CAL 25047
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tsha-20200930_def.xml EX-101.DEF 216531
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20200930_lab.xml EX-101.LAB 379522
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20200930_pre.xml EX-101.PRE 314024
Mailing Address 7318 MORTON STREET DALLAS TX 75209
Business Address 7318 MORTON STREET DALLAS TX 75209 212.551.8702
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39536 | Film No.: 201307140
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences